a Department of Radiation Oncology, Korea University Ansan Hospital , Gyeonggido , Republic of Korea.
b Biomedical Research Center Korea University Ansan Hospital , Gyeonggido , Republic of Korea.
Int J Radiat Biol. 2019 Aug;95(8):1150-1159. doi: 10.1080/09553002.2019.1590661. Epub 2019 Apr 1.
Radioprotectors can enhance the efficacy of cancer radiotherapy, but their clinical use remains uncommon. The present study aimed to assess the radioprotective potential of mistletoe extract (commercial name: Abnoba Viscum), a well-known complementary cancer medicine, in zebrafish larvae. Wild-type AB zebrafish embryos at 4 h-post-fertilization were exposed to 5 Gy 9-MeV electron beam irradiation after being treated for 1 h with 4 mMl/L amifostine or 0.2 mg/ml Abnoba Viscum A, F, M, or Q. Primary endpoints were abnormality-free survival and abnormality-free rates among survivors at 5 days-post-fertilization. The crude abnormality-free survival rates were 33.7%, 49.0%, 38.8%, 43.9%, 38.1%, and 52.6%, whereas abnormality-free rates among survivors were 36.4%, 49.6%, 37.8%, 45.6%, 52.0%, and 62.8% for the control (with no pharmacologic treatment), amifostine, Abnoba Viscum A, F, M, and Q groups, respectively. Abnormality-free survival rates in the amifostine and Abnoba Viscum Q groups were significantly different from those in the control ( = .040 and .012, respectively), with an odds ratio (OR) of 1.90 [95% confidence interval (CI): 1.03-3.51] and 2.20 (95% CI: 1.19-4.08), respectively. Abnormality-free rates among survivors in the amifostine and Abnoba Viscum M and Q groups were significantly different from those in the control group ( = .048, .042, and <.001, respectively), with an OR of 1.79 (95% CI: 1.00-3.20), 1.82 (95% CI: 1.02-3.26), and 2.98 (1.67-5.33), respectively. Abnoba Viscum Q has at least a similar radioprotective effect to that of amifostine. Mistletoe extracts have been clinically applied for a long time and their effectiveness and feasibility have been verified. Abnoba Viscum Q might be a new candidate radioprotectant to enhance cancer radiotherapy efficacy.
放射防护剂可增强癌症放疗的疗效，但临床应用仍不常见。本研究旨在评估一种知名的癌症辅助治疗药物——槲寄生提取物（商品名：Abnoba Viscum）在斑马鱼幼虫中的放射防护潜力。 将野生型 AB 斑马鱼胚胎在受精后 4 小时进行 5Gy9-MeV 电子束照射，照射前 1 小时用 4mM/L 氨磷汀或 0.2mg/ml Abnoba Viscum A、F、M 或 Q 处理。主要终点为受精后 5 天无畸形的存活率和幸存者的无畸形率。 粗无畸形存活率分别为 33.7%、49.0%、38.8%、43.9%、38.1%和 52.6%，而幸存者的无畸形率分别为 36.4%、49.6%、37.8%、45.6%、52.0%和 62.8%，对照组（无药物治疗）、氨磷汀、Abnoba Viscum A、F、M 和 Q 组。 氨磷汀组和 Abnoba Viscum Q 组的无畸形存活率与对照组有显著差异（ = .040 和.012），优势比（OR）分别为 1.90（95%置信区间（CI）：1.03-3.51）和 2.20（95% CI：1.19-4.08）。 氨磷汀组和 Abnoba Viscum M 和 Q 组的幸存者无畸形率与对照组有显著差异（ = .048，.042 和 <.001），OR 分别为 1.79（95% CI：1.00-3.20）、1.82（95% CI：1.02-3.26）和 2.98（1.67-5.33）。 Abnoba Viscum Q 具有与氨磷汀相似的放射防护作用。槲寄生提取物已在临床上应用了很长时间，其有效性和可行性已得到验证。Abnoba Viscum Q 可能是一种增强癌症放疗疗效的新候选放射防护剂。
